Abstract: A pharmaceutical composition containing a drug encapsulated in a polymer micelle composition containing a first block copolymer having affinity with HDL and a second block copolymer having affinity with a lipoprotein excluding HDL, each block copolymer having a hydrophobic polymer chain segment and a hydrophilic polymer chain segment such that a plurality of block copolymers arrange radially with the hydrophobic segments directed inward and the hydrophilic segments directed outward. In the composition, a detachment of the first block copolymer is induced by HDL adhesion which forms a gap and promotes the release of a drug encapsulated, while the second block copolymer excluding an affinity with HDL controls a release speed of the drug encapsulated.

Abstract: The present invention provides a block copolymer for a drug conjugate which comprises a water-soluble polymer region consisting of polyethylene glycol and a polyamino acid region having a hydrazide group and a hydrophobic group in the side chain.

Abstract: A pharmaceutical composition or combination drug, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by the following formula I or formula II and cisplatin, and (b) gemcitabine hydrochloride. In the formulae I and II, R1, A, R2, R3, m and n are as defined in the description.

Abstract: The present invention provides a cationic polyamino acid suitable for a carrier that can form a stable complex with a nucleic acid under a physiological condition and release the nucleic acid in cells suitably. The cationic polyamino acid can associate with a nucleic acid and includes a cationic amino acid residue having a cationic group in a side chain and a hydrophobic amino acid residue having a hydrophobic group in a side chain. The cationic polyamino acid includes 1 to 20 units of the cationic amino acid residue and is represented by the following formula (1). The meaning of each symbol in the formula is as shown in the description.

Abstract: A pharmaceutical composition containing a drug encapsulated in a polymer micelle composition containing a first block copolymer having affinity with HDL and a second block copolymer having affinity with a lipoprotein excluding HDL, each block copolymer having a hydrophobic polymer chain segment and a hydrophilic polymer chain segment such that a plurality of block copolymers arrange radially with the hydrophobic segments directed inward and the hydrophilic segments directed outward. In the composition, a detachment of the first block copolymer is induced by HDL adhesion which forms a gap and promotes the release of a drug encapsulated, while the second block copolymer excluding an affinity with HDL controls a release speed of the drug encapsulated.

Abstract: The invention provides a physiologically active polypeptide- or protein-encapsulating polymer micelle composition derived from a block copolymer comprising hydrophilic segments and hydrophobic segments.

Abstract: The present invention provides an active targeting polymer micelle encapsulating a drug, preventing an inappropriate release of a drug which may damage a normal cell. A polymer micelle 100 includes a backbone polymer unit 10 that has a target binding site 11 and a backbone polymer unit 20 that has a drug 14 and is free from the target binding site 11, such polymer units 10 and 20 being disposed in a radial arrangement in a state where the target binding site 11 is directed outward and the drug 14 is directed inward, in which: i) when the micelle is bound to a target 40 while maintaining the radial arrangement, the micelle is taken up into a cell 50 supplying the target 40 through endocytosis, and the drug 14 is released into the cell 50 by collapse of the radial arrangement in the cell 50; and ii) when the radial arrangement collapses in blood 60 before the micelle is bound to a target 40, the unit 20 is excreted through metabolism, to thereby prevent a normal cell from being damaged by the drug 14.

Abstract: There is provided a production method in which bis(nitrato)platinum complex, optionally in the concurrent presence of dihalo-platinum complex, and poly(ethylene glycol)-block-poly(glutamic acid) are used at specific ratios and reacted. Coordination compound of an anti-tumor platinum complex with a block copolymer having carboxyl groups on its side chains is efficiently produced.

Abstract: This invention provides a method to effectively incorporate inorganic fluorescent substance or inorganic contrast medium into latex polymer particles which are used for diagnostic test or the like, and also provides thus produced fluorescent substance-containing latex polymer particles which show decreased non-specific adsorption of protein or the like. Said latex polymer particles are produced by making latex-forming monomer, macromer which has at least a hydrophilic polymer segment and an inorganic fluorescent substance or an inorganic contrast medium co-existent simultaneously in an aqueous medium, and subjecting them to a polymerization reaction.

Abstract: Provided are a production process for a polymeric micelle which is stable and has a high drug content and a composition containing such polymeric micelle. Disclosed are a production process for a polymeric micelle, comprising the steps of dissolving a drug and a specific copolymer in a water non-miscible organic solvent to prepare a solution, mixing the resulting solution with water to form an O/W type emulsion and then slowly volatilizing the organic solvent from the solution, and a polymeric micelle composition charged therein with a water-scarcely soluble drug, which can be obtained by the above production process.

Abstract: A production method of a preparation containing drug-encapsulating polymer micelles is provided, which comprises dissolving a hydrophilic-hydrophobic block copolymer and a sparingly water-soluble drug in a volatile organic solvent, then removing the solvent, and stirring the residue with water at a temperature not higher than 30° C. to dissolve the drug-encapsulating polymer micelles into the water.

Abstract: Disclosed are block copolymers represented by the following general formula (I) wherein AI represents a hydroxyl group or an organic residue derived from an anionic polymerization initiator, R represents a hydrogen atom or an acyl group, NP represents a residue derived from a nucleophilic reagent, m is an integer of 2 to 20,000, and n is an integer of 1 to 20,000.

Abstract: A core-shell particle including a signal-generating substance therein, wherein the core-shell particle consists of (1) a core portion substantially made of a water-insoluble polymer compound; and (2) a shell portion substantially made of a water-soluble polymer compound having a reactive functional group, and covering a surface of the core portion in the manner of bristles of a brush; and the core portion and the shell portion are, as a whole, a block copolymer of a water-insoluble polymer and a water-soluble polymer, characterized in that the signal-generating substance is included in the core portion, is disclosed, and a process for producing the same is also disclosed. The core-shell particle including a signal-generating substance therein is useful as a labeling substance in which neither radioisotopes having handling restrictions nor unstable enzymes are required, a high sensitivity superior to fluorescent substances is achieved, and nonspecific absorption does not occur.

Abstract: Provided are a production process for a polymeric micelle which is stable and has a high drug content and a composition containing such polymeric micelle. Disclosed are a production process for a polymeric micelle, comprising the steps of dissolving a drug and a specific copolymer in a water non-miscible organic solvent to prepare a solution, mixing the resulting solution with water to form an O/W type emulsion and then slowly volatilizing the organic solvent from the solution, and a polymeric micelle composition charged therein with a water-scarcely soluble drug, which can be obtained by the above production process.